After discussion by a multidisciplinary team, patients completing neoadjuvant treatment, clinical stage T2 or N1 ER+/PR+/HER2 negative tumors, triple-negative or HER2 positive patients, discordant biopsies likely to be malignant, and patients with locoregional recurrence were prioritized over excisions of benign lesions, fibroadenomas, papillomas, high risk lesions with atypia, and prophylactic surgeries (risk reducing surgeries). The gene discussed is ERBB2; the disease is papilloma.